Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Phase 3 clinical trial investigating the effect of selenium supplementation in men at high-risk for prostate cancer.

Algotar AM, Stratton MS, Ahmann FR, Ranger-Moore J, Nagle RB, Thompson PA, Slate E, Hsu CH, Dalkin BL, Sindhwani P, Holmes MA, Tuckey JA, Graham DL, Parnes HL, Clark LC, Stratton SP.

Prostate. 2013 Feb 15;73(3):328-35. doi: 10.1002/pros.22573. Epub 2012 Aug 10.

2.

Oral selenium supplementation has no effect on prostate-specific antigen velocity in men undergoing active surveillance for localized prostate cancer.

Stratton MS, Algotar AM, Ranger-Moore J, Stratton SP, Slate EH, Hsu CH, Thompson PA, Clark LC, Ahmann FR.

Cancer Prev Res (Phila). 2010 Aug;3(8):1035-43. doi: 10.1158/1940-6207.CAPR-09-0143. Epub 2010 Jul 20.

3.

A randomized double-blind placebo controlled phase I-II study on clinical and molecular effects of dietary supplements in men with precancerous prostatic lesions. Chemoprevention or "chemopromotion"?

Gontero P, Marra G, Soria F, Oderda M, Zitella A, Baratta F, Chiorino G, Gregnanin I, Daniele L, Cattel L, Frea B, Brusa P.

Prostate. 2015 Aug 1;75(11):1177-86. doi: 10.1002/pros.22999. Epub 2015 Apr 20.

PMID:
25893930
4.

Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman SM, Goodman GE, Meyskens FL Jr, Baker LH.

JAMA. 2011 Oct 12;306(14):1549-56. doi: 10.1001/jama.2011.1437.

5.

Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial.

Duffield-Lillico AJ, Dalkin BL, Reid ME, Turnbull BW, Slate EH, Jacobs ET, Marshall JR, Clark LC; Nutritional Prevention of Cancer Study Group.

BJU Int. 2003 May;91(7):608-12.

6.

Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD 3rd, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL Jr, Baker LH, Coltman CA Jr.

JAMA. 2009 Jan 7;301(1):39-51. doi: 10.1001/jama.2008.864. Epub 2008 Dec 9.

7.

Selenium and prevention of prostate cancer in high-risk men: the Negative Biopsy Study.

Stratton MS, Reid ME, Schwartzberg G, Minter FE, Monroe BK, Alberts DS, Marshall JR, Ahmann FR.

Anticancer Drugs. 2003 Sep;14(8):589-94.

PMID:
14501380
8.

Antioxidant vitamin and mineral supplementation and prostate cancer prevention in the SU.VI.MAX trial.

Meyer F, Galan P, Douville P, Bairati I, Kegle P, Bertrais S, Estaquio C, Hercberg S.

Int J Cancer. 2005 Aug 20;116(2):182-6.

9.

Selenium supplementation has no effect on serum glucose levels in men at high risk of prostate cancer.

Algotar AM, Hsu CH, Singh P, Stratton SP.

J Diabetes. 2013 Dec;5(4):465-70. doi: 10.1111/1753-0407.12041. Epub 2013 May 29.

10.

Selenium and inhibition of disease progression in men diagnosed with prostate carcinoma: study design and baseline characteristics of the 'Watchful Waiting' Study.

Stratton MS, Reid ME, Schwartzberg G, Minter FE, Monroe BK, Alberts DS, Marshall JR, Ahmann FR.

Anticancer Drugs. 2003 Sep;14(8):595-600.

PMID:
14501381
11.

Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917.

Marshall JR, Tangen CM, Sakr WA, Wood DP Jr, Berry DL, Klein EA, Lippman SM, Parnes HL, Alberts DS, Jarrard DF, Lee WR, Gaziano JM, Crawford ED, Ely B, Ray M, Davis W, Minasian LM, Thompson IM Jr.

Cancer Prev Res (Phila). 2011 Nov;4(11):1761-9. doi: 10.1158/1940-6207.CAPR-10-0343. Epub 2011 Sep 6.

12.

Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial.

Duffield-Lillico AJ, Reid ME, Turnbull BW, Combs GF Jr, Slate EH, Fischbach LA, Marshall JR, Clark LC.

Cancer Epidemiol Biomarkers Prev. 2002 Jul;11(7):630-9.

13.

A report of high-dose selenium supplementation: response and toxicities.

Reid ME, Stratton MS, Lillico AJ, Fakih M, Natarajan R, Clark LC, Marshall JR.

J Trace Elem Med Biol. 2004;18(1):69-74.

PMID:
15487766
15.

Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk.

Kristal AR, Darke AK, Morris JS, Tangen CM, Goodman PJ, Thompson IM, Meyskens FL Jr, Goodman GE, Minasian LM, Parnes HL, Lippman SM, Klein EA.

J Natl Cancer Inst. 2014 Mar;106(3):djt456. doi: 10.1093/jnci/djt456. Epub 2014 Feb 22.

16.

Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial.

Clark LC, Dalkin B, Krongrad A, Combs GF Jr, Turnbull BW, Slate EH, Witherington R, Herlong JH, Janosko E, Carpenter D, Borosso C, Falk S, Rounder J.

Br J Urol. 1998 May;81(5):730-4.

PMID:
9634050
17.

No effect of selenium supplementation on serum glucose levels in men with prostate cancer.

Algotar AM, Stratton MS, Stratton SP, Hsu CH, Ahmann FR.

Am J Med. 2010 Aug;123(8):765-8. doi: 10.1016/j.amjmed.2010.02.018.

18.

Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study.

Marberger M, Freedland SJ, Andriole GL, Emberton M, Pettaway C, Montorsi F, Teloken C, Rittmaster RS, Somerville MC, Castro R.

BJU Int. 2012 Apr;109(8):1162-9. doi: 10.1111/j.1464-410X.2011.10373.x. Epub 2011 Jun 23.

20.

Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.

Thompson IM, Pauler Ankerst D, Chi C, Goodman PJ, Tangen CM, Lippman SM, Lucia MS, Parnes HL, Coltman CA Jr.

J Clin Oncol. 2007 Jul 20;25(21):3076-81.

PMID:
17634486

Supplemental Content

Support Center